miR-1285-3p acts as a potential tumor suppressor miRNA via downregulating JUN expression in hepatocellular carcinoma

Tumor Biology

Volumn 36, Issue 1, 2015, Pages 219-225

  Liu, Jibing ^a   Yan, Jingchen ^b   Zhou, Changchun ^a   Ma, Qinghua ^a   Jin, Qingyan ^a   Yang, Zhenbin ^c  

^a SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

^b Department of Intervention ^*  (China)

^c Clinical Laboratory Medicine Liaocheng Isolation Hospital   (China)

Author keywords

HCC; JUN; miR 1285 3p; Plasma; Prognosis; TACE

Indexed keywords

MICRORNA; MICRORNA 1285 3P; MICRORNA 4741; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; MIRN1285 MICRORNA, HUMAN; PROTEIN C JUN;

3' UNTRANSLATED REGION; ADULT; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER PROGNOSIS; CHEMOEMBOLIZATION; CLINICAL EFFECTIVENESS; DOWN REGULATION; FEMALE; GENE EXPRESSION; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; ONCOGENE C JUN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSARTERIAL CHEMOEMBOLIZATION; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE; AGED; BLOOD; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; GENE EXPRESSION REGULATION; GENETICS; LIVER NEOPLASMS; METABOLISM; MIDDLE AGED; PHYSIOLOGY; PROGNOSIS; RNA INTERFERENCE; TUMOR CELL LINE;

3' UNTRANSLATED REGIONS; AGED; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMOEMBOLIZATION, THERAPEUTIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; LIVER NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-JUN; RNA INTERFERENCE;

EID: 84922265621     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2622-5     Document Type: Article

References (32)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.
2. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557–76.
3. Tang ZY, Ye SL, Liu YK, Qin LX, Sun HC, Ye QH, et al. A decade’s studies on metastasis of hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130(4):187–96.
4. Vogl TJ, Naguib NN, Nour-Eldin NE, Rao P, Emami AH, Zangos S, et al. Review on transarterial chemoembolization in hepatocellular carcinoma: palliative, combined, neoadjuvant, bridging, and symptomatic indications. Eur J Radiol. 2009;72(3):505–16.
5. Gottesman S. Small RNAs shed some light. Cell. 2004;118(1):1–2.
6. Caldas C, Brenton JD. Sizing up miRNAs as cancer genes. Nat Med. 2005;11(7):712–4.
7. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435(7043):834–8.
8. Liu J, Tang X, Li M, Lu C, Shi J, Zhou L, et al. Functional MDM4 rs4245739 genetic variant, alone and in combination with P53 Arg72Pro polymorphism, contributes to breast cancer susceptibility. Breast Cancer Res Treat. 2013;140(1):151–7.
9. Zhou L, Zhang X, Li Z, Zhou C, Li M, Tang X, et al. Association of a genetic variation in a miR-191 binding site in MDM4 with risk of esophageal squamous cell carcinoma. PLoS One. 2013;8(5):e64331.
10. Zhang X, Wei J, Zhou L, Zhou C, Shi J, Yuan Q, et al. A functional BRCA1 coding sequence genetic variant contributes to risk of esophageal squamous cell carcinoma. Carcinogenesis. 2013;34(10):2309–13.
11. Yao J, Liu L, Yang M. Interleukin-23 receptor genetic variants contribute to susceptibility of multiple cancers. Gene. 2014;533(1):21–5.
12. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology. 2007;133(2):647–58.
13. Kota J, Chivukula RR, O′Donnell KA, Wentzel EA, Montgomery CL, Hwang HW, et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell. 2009;137(6):1005–17.
14. Ding J, Huang S, Wu S, Zhao Y, Liang L, Yan M, et al. Gain of miR-151 on chromosome 8q24.3 facilitates tumour cell migration and spreading through downregulating RhoGDIA. Nat Cell Biol. 2010;12(4):390–9.
15. Hou J, Lin L, Zhou W, Wang Z, Ding G, Dong Q, et al. Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell. 2011;19(2):232–43.
16. Zhou C, Liu J, Li Y, Liu L, Zhang X, Ma CY, et al. microRNA-1274a, a modulator of sorafenib induced a disintegrin and metalloproteinase 9 (ADAM9) down-regulation in hepatocellular carcinoma. FEBS Lett. 2011;585(12):1828–34.
17. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105(30):10513–8.
18. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008;18(10):997–1006.
19. Wang K, Zhang S, Marzolf B, Troisch P, Brightman A, Hu Z, et al. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci U S A. 2009;106(11):4402–7.
20. Laterza OF, Lim L, Garrett-Engele PW, Vlasakova K, Muniappa N, Tanaka WK, et al. Plasma MicroRNAs as sensitive and specific biomarkers of tissue injury. Clin Chem. 2009;55(11):1977–83.
21. Starkey Lewis PJ, Dear J, Platt V, Simpson KJ, Craig DG, Antoine DJ, et al. Circulating microRNAs as potential markers of human drug-induced liver injury. Hepatology. 2011;54(5):1767–76.
22. Tian S, Huang S, Wu S, Guo W, Li J, He X. MicroRNA-1285 inhibits the expression of p53 by directly targeting its 3′ untranslated region. Biochem Biophys Res Commun. 2010;396(2):435–9.
23. Shaulian E. AP-1—the Jun proteins: Oncogenes or tumor suppressors in disguise? Cell Signal. 2010;22(6):894–9.
24. Shaulian E, Karin M. AP-1 as a regulator of cell life and death. Nat Cell Biol. 2002;4(5):E131–6.
25. Lamph WW, Wamsley P, Sassone-Corsi P, Verma IM. Induction of proto-oncogene JUN/AP-1 by serum and TPA. Nature. 1988;334(6183):629–31.
26. Milde-Langosch K. The Fos family of transcription factors and their role in tumourigenesis. Eur J Cancer. 2005;41(16):2449–61.
27. Bohmann D, Bos TJ, Admon A, Nishimura T, Vogt PK, Tjian R. Human proto-oncogene c-jun encodes a DNA binding protein with structural and functional properties of transcription factor AP-1. Science. 1987;238(4832):1386–92.
28. Maki Y, Bos TJ, Davis C, Starbuck M, Vogt PK. Avian sarcoma virus 17 carries the jun oncogene. Proc Natl Acad Sci U S A. 1987;84(9):2848–52.
29. Eferl R, Ricci R, Kenner L, Zenz R, David JP, Rath M, et al. Liver tumor development. c-Jun antagonizes the proapoptotic activity of p53. Cell. 2003;112(2):181–92.
30. Machida K, Tsukamoto H, Liu JC, Han YP, Govindarajan S, Lai MM, et al. c-Jun mediates hepatitis C virus hepatocarcinogenesis through signal transducer and activator of transcription 3 and nitric oxide-dependent impairment of oxidative DNA repair. Hepatology. 2010;52(2):480–92.
31. Watanabe T, Hiasa Y, Tokumoto Y, Hirooka M, Abe M, Ikeda Y, et al. Protein kinase R modulates c-Fos and c-Jun signaling to promote proliferation of hepatocellular carcinoma with hepatitis C virus infection. PLoS One. 2013;8(7):e67750.
32. Yang Z, Zhang Y, Wang L. A feedback inhibition between miRNA-127 and TGFβ/c-Jun cascade in HCC cell migration via MMP13. PLoS One. 2013;8(6):e65256.